Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in idiopathic pulmonary arterial hypertension – feasibility study
2022-002400-20Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Plexogenic Pulmonary Arteriopathy comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Feasibility, safety, and tolerability over 12 weeks. Started Feb 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
Plexogenic Pulmonary Arteriopathy
Beyond the preview
Go deeper on 2022-002400-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002400-20.